News >

Lead IMPACT Investigator Discusses Precision Medicine Across Tumor Types

Jason Harris
Published: Wednesday, Oct 31, 2018

Apostolia-Maria Tsimberidou, MD, PhD

Apostolia-Maria Tsimberidou, MD, PhD
The use of targeted matched therapy more than doubled 3-year overall survival (OS) in patients with refractory cancers compared with those who received nonmatched therapy, according to results from the IMPACT trial.

Lead author Apostolia-Maria Tsimberidou, MD, PhD, professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, presented these results at the 2018 ASCO Annual Meeting. She said that findings from studies like IMPACT exploring precision medicine could play a major role in cancer care, especially for patients with rare or difficult-to-treat diseases.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication